Lenabasum

DB12193InvestigationalSmall molecule

Ajulemic acid has been used in trials studying the treatment of Cystic Fibrosis, Dermatomyositis, and Diffuse Cutaneous Systemic Sclerosis.

Chemical structure of Lenabasum
Formula / weight
C25H36O4 · 400.5509 g/mol (avg)
Also known as
(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid · Ajulemic acid · Anabasum
Code names
CPL-7075 · CT-3 · HU-239 · IP-751 · JBT-101 · Resunab

Resolves to

Compound
UNIIOGN7X90BT8CAS137945-48-3ChEMBLCHEMBL456341PubChem3083542
Structure
InChIKeyYCHYFHOSGQABSW-RTBURBONSA-NSMILES[H][C@@]12CC(=CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC)C(O)=O
Targets
P01375TNF

What you can answer from here — as of October 30, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
841Drug interactionsStructured to mechanism, not free text
Sign in
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Lenabasum, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In